CRL for Novartis’s Inclisiran (PCSK9i)
Here is a brief preview of this blast: Novartis announced it has received a CRL from FDA for the inclisiran NDA. According to the press release, the CRL is not related to efficacy or safety concerns, but rather, it was "due to unresolved facility inspection-related conditions." Recall, the EC granted marketing authorization for inclisiran on December 11, 2020 (view press release). Below, FENIX provides brief thoughts on the inclisiran CRL.